Skip to content
Sign in
StableHealthReported 2026-11-19 15:48

Implantica Reports Q3 2026 Interim Results with FDA Approval and U.S. Launch

Implantica secured FDA approval for RefluxStop® and launched in the U.S., with significant sales growth in Europe. The company also reported financial results for Q3 2026.

Why it matters. Implantica's U.S. launch and FDA approval for RefluxStop® will impact its market presence and financial performance.

01

Who and what it touches

RefluxStoppart ofeHealthusesMedtechoperates inUnited Statesoperates inwireless powerusesImplantica

Into Implantica

From Implantica

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-19 15:48
    Operating loss (EBIT) amounted to TEUR 4,511 (4,432).
    View source